In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Ricardo RodriguesUnidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.ORCID 0000-0003-1928-4106 Beatriz GarciaUnidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.ORCID 0009-0009-7771-5331 Miguel RitoServiço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.ORCID 0000-0002-0226-5905 Rúben RoqueServiço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.ORCID 0000-0003-2368-4516 Teresa PereiraServiço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.
Sónia MorgadoServiço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.
Vanessa TavaresServiço de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.
Tiago Nunes da SilvaUnidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.
Valeriano LeiteUnidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.ORCID 0000-0001-5479-7332 Branca Maria CavacoUnidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Professor Lima Basto, 1099-023 Lisboa, Portugal.ORCID 0000-0001-8946-8635 Funding
Associação de Endocrinologia Oncológica (AEO)Associated Laboratory LS4FUTURE doi: 10.54499/LA/P/0087/2020Fundação para a Ciência e Tecnologia/Ministério da Ciência, Tecnologia e Ensino SuperioriNOVA4Health - Programme in Translational Medicine Unit UID/04462; UID/PRR/04462/2025 - https://doi.org/10.54499/UID/PRR/04462/2025iNOVA4Health Research Unit UIDP/04462/2020; UI/BD/154256/2022 (https://doi.org/10.54499/UI/BD/154256/2022)Instituto Português de Oncologia de Lisboa Francisco Gentil
6 · The paper itselfAbstract
Anaplastic thyroid carcinoma (ATC) is an aggressive malignancy with poor response to standard therapies. While Dabrafenib plus Trametinib (DT) combination therapy has improved the survival of patients with
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmImidazolesMacrophagesOximesPyridonesPyrimidinonesThyroid Carcinoma, AnaplasticThyroid NeoplasmsCell Line, TumorCell SurvivalCoculture TechniquesHumansProto-Oncogene Proteins B-rafdabrafenibImidazolesOximesProto-Oncogene Proteins B-rafPyridonesPyrimidinonestrametinibanaplastic thyroid carcinomaDabrafenib plus TrametinibmacrophagesSPRY4
Identifiers
PMID42737588
PMCPMC13565890
What OpenQuestion holds
Textmetadata
Read underepoch 390